Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil
Background We compared the efficacy and toxicity of oral capecitabine and continuous infusion of 5‐fluorouracil (5‐FU) in the preoperative chemoradiation treatment of patients with rectal cancer. Patients and Methods The files of 89 patients with rectal cancer, 43 treated preoperatively with oral ca...
Gespeichert in:
| Veröffentlicht in: | Journal of surgical oncology 2006-06, Vol.93 (7), p.529-533 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 533 |
|---|---|
| container_issue | 7 |
| container_start_page | 529 |
| container_title | Journal of surgical oncology |
| container_volume | 93 |
| creator | Yerushalmi, Rinat Idelevich, Efraim Dror, Ygael Stemmer, Salomon M. Figer, Arie Sulkes, Aaron Brenner, Baruch Loven, David Dreznik, Zeev Nudelman, Israel Shani, Adi Fenig, Eyal |
| description | Background
We compared the efficacy and toxicity of oral capecitabine and continuous infusion of 5‐fluorouracil (5‐FU) in the preoperative chemoradiation treatment of patients with rectal cancer.
Patients and Methods
The files of 89 patients with rectal cancer, 43 treated preoperatively with oral capecitabine and 46 with intravenous 5‐FU, were reviewed, and the outcome of the groups was compared.
Results
There was no statistically significant difference in the complete pathological response rate between the capecitabine and the 5‐FU groups (30% vs. 17%, P = 0.15). The downstaging rate was higher in the capecitabine group (77% vs. 50%, P = 0.009). Toxicity was mild in both groups. The rate of Grade 3 gastrointestinal toxicity was similar in the two groups (diarrhea 2% vs. 4%, proctitis 5% vs. 7%), except for one patient in the 5‐FU group (2%) who developed a rectovaginal fistula. In the capecitabine group, one patient (2%) had Grade 3 hand‐foot syndrome, and another had an acute myocardial infarction. In the 5‐FU group, two patients (4%) had Grade 3 hematological toxicity, and three (6%) had complications from Port‐a‐Cath insertion.
Conclusion
Preoperative chemoradiation with oral capecitabine appears to be safe and well tolerated, and at least as good as continuous 5‐FU. J. Surg. Oncol. 2006;93:529–533. © 2006 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/jso.20503 |
| format | Article |
| fullrecord | <record><control><sourceid>istex_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_jso_20503</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_3ZXKX735_Q</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4273-86ce037c37711459e40e76f44497493137e7148a036087dafc25275de16ae4e43</originalsourceid><addsrcrecordid>eNp1kMlOxDAMhiMEYoblwAugXjkUnCZtJtwQYkfsCMQlyqSuCHSaKmlZHoD3JjADnDhZtj9_kn9C1ihsUoBs6ym4zQxyYHNkSEEWqQQ5mifDuMtSLiQMyFIITwAgZcEXyYAWAnKRZUPyceHRteh1Z18wMY84cV6XNrauSWyTeDSdrhOjG4N-O7nCzrvQxuE37iat9jZEdIzdK2ITwbi0nR7bBhPdlJFpOtv0rg9RV_Xhy-uqJE-runfe9V4bW6-QhUrXAVdndZnc7u_d7B6mp-cHR7s7p6nhmWDpqDAITBgmBKU8l8gBRVFxzqXgklEmUFA-0sAKGIlSVybLM5GXSAuNHDlbJhtTr4lfBI-Var2daP-uKKivKFWMUn1HGdn1Kdv24wmWf-QsuwhsTYFXW-P7_yZ1fH3-o0ynFzZ0-PZ7of2zKgQTubo7O1Ds4f7kXrBcXbJP2m-PUA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Yerushalmi, Rinat ; Idelevich, Efraim ; Dror, Ygael ; Stemmer, Salomon M. ; Figer, Arie ; Sulkes, Aaron ; Brenner, Baruch ; Loven, David ; Dreznik, Zeev ; Nudelman, Israel ; Shani, Adi ; Fenig, Eyal</creator><creatorcontrib>Yerushalmi, Rinat ; Idelevich, Efraim ; Dror, Ygael ; Stemmer, Salomon M. ; Figer, Arie ; Sulkes, Aaron ; Brenner, Baruch ; Loven, David ; Dreznik, Zeev ; Nudelman, Israel ; Shani, Adi ; Fenig, Eyal</creatorcontrib><description>Background
We compared the efficacy and toxicity of oral capecitabine and continuous infusion of 5‐fluorouracil (5‐FU) in the preoperative chemoradiation treatment of patients with rectal cancer.
Patients and Methods
The files of 89 patients with rectal cancer, 43 treated preoperatively with oral capecitabine and 46 with intravenous 5‐FU, were reviewed, and the outcome of the groups was compared.
Results
There was no statistically significant difference in the complete pathological response rate between the capecitabine and the 5‐FU groups (30% vs. 17%, P = 0.15). The downstaging rate was higher in the capecitabine group (77% vs. 50%, P = 0.009). Toxicity was mild in both groups. The rate of Grade 3 gastrointestinal toxicity was similar in the two groups (diarrhea 2% vs. 4%, proctitis 5% vs. 7%), except for one patient in the 5‐FU group (2%) who developed a rectovaginal fistula. In the capecitabine group, one patient (2%) had Grade 3 hand‐foot syndrome, and another had an acute myocardial infarction. In the 5‐FU group, two patients (4%) had Grade 3 hematological toxicity, and three (6%) had complications from Port‐a‐Cath insertion.
Conclusion
Preoperative chemoradiation with oral capecitabine appears to be safe and well tolerated, and at least as good as continuous 5‐FU. J. Surg. Oncol. 2006;93:529–533. © 2006 Wiley‐Liss, Inc.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.20503</identifier><identifier>PMID: 16705722</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Capecitabine ; continuous-infusion 5-FU ; Deoxycytidine - administration & dosage ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Diarrhea - chemically induced ; Drug Administration Schedule ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Neoadjuvant Therapy ; preoperative chemoradiation ; rectal cancer ; Rectal Neoplasms - drug therapy ; Rectal Neoplasms - pathology ; Rectal Neoplasms - radiotherapy ; Rectal Neoplasms - surgery ; Retrospective Studies ; Treatment Outcome</subject><ispartof>Journal of surgical oncology, 2006-06, Vol.93 (7), p.529-533</ispartof><rights>Copyright © 2006 Wiley‐Liss, Inc.</rights><rights>Copyright 2006 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4273-86ce037c37711459e40e76f44497493137e7148a036087dafc25275de16ae4e43</citedby><cites>FETCH-LOGICAL-c4273-86ce037c37711459e40e76f44497493137e7148a036087dafc25275de16ae4e43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.20503$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.20503$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16705722$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yerushalmi, Rinat</creatorcontrib><creatorcontrib>Idelevich, Efraim</creatorcontrib><creatorcontrib>Dror, Ygael</creatorcontrib><creatorcontrib>Stemmer, Salomon M.</creatorcontrib><creatorcontrib>Figer, Arie</creatorcontrib><creatorcontrib>Sulkes, Aaron</creatorcontrib><creatorcontrib>Brenner, Baruch</creatorcontrib><creatorcontrib>Loven, David</creatorcontrib><creatorcontrib>Dreznik, Zeev</creatorcontrib><creatorcontrib>Nudelman, Israel</creatorcontrib><creatorcontrib>Shani, Adi</creatorcontrib><creatorcontrib>Fenig, Eyal</creatorcontrib><title>Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil</title><title>Journal of surgical oncology</title><addtitle>J. Surg. Oncol</addtitle><description>Background
We compared the efficacy and toxicity of oral capecitabine and continuous infusion of 5‐fluorouracil (5‐FU) in the preoperative chemoradiation treatment of patients with rectal cancer.
Patients and Methods
The files of 89 patients with rectal cancer, 43 treated preoperatively with oral capecitabine and 46 with intravenous 5‐FU, were reviewed, and the outcome of the groups was compared.
Results
There was no statistically significant difference in the complete pathological response rate between the capecitabine and the 5‐FU groups (30% vs. 17%, P = 0.15). The downstaging rate was higher in the capecitabine group (77% vs. 50%, P = 0.009). Toxicity was mild in both groups. The rate of Grade 3 gastrointestinal toxicity was similar in the two groups (diarrhea 2% vs. 4%, proctitis 5% vs. 7%), except for one patient in the 5‐FU group (2%) who developed a rectovaginal fistula. In the capecitabine group, one patient (2%) had Grade 3 hand‐foot syndrome, and another had an acute myocardial infarction. In the 5‐FU group, two patients (4%) had Grade 3 hematological toxicity, and three (6%) had complications from Port‐a‐Cath insertion.
Conclusion
Preoperative chemoradiation with oral capecitabine appears to be safe and well tolerated, and at least as good as continuous 5‐FU. J. Surg. Oncol. 2006;93:529–533. © 2006 Wiley‐Liss, Inc.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Capecitabine</subject><subject>continuous-infusion 5-FU</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - adverse effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Diarrhea - chemically induced</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>preoperative chemoradiation</subject><subject>rectal cancer</subject><subject>Rectal Neoplasms - drug therapy</subject><subject>Rectal Neoplasms - pathology</subject><subject>Rectal Neoplasms - radiotherapy</subject><subject>Rectal Neoplasms - surgery</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMlOxDAMhiMEYoblwAugXjkUnCZtJtwQYkfsCMQlyqSuCHSaKmlZHoD3JjADnDhZtj9_kn9C1ihsUoBs6ym4zQxyYHNkSEEWqQQ5mifDuMtSLiQMyFIITwAgZcEXyYAWAnKRZUPyceHRteh1Z18wMY84cV6XNrauSWyTeDSdrhOjG4N-O7nCzrvQxuE37iat9jZEdIzdK2ITwbi0nR7bBhPdlJFpOtv0rg9RV_Xhy-uqJE-runfe9V4bW6-QhUrXAVdndZnc7u_d7B6mp-cHR7s7p6nhmWDpqDAITBgmBKU8l8gBRVFxzqXgklEmUFA-0sAKGIlSVybLM5GXSAuNHDlbJhtTr4lfBI-Var2daP-uKKivKFWMUn1HGdn1Kdv24wmWf-QsuwhsTYFXW-P7_yZ1fH3-o0ynFzZ0-PZ7of2zKgQTubo7O1Ds4f7kXrBcXbJP2m-PUA</recordid><startdate>20060601</startdate><enddate>20060601</enddate><creator>Yerushalmi, Rinat</creator><creator>Idelevich, Efraim</creator><creator>Dror, Ygael</creator><creator>Stemmer, Salomon M.</creator><creator>Figer, Arie</creator><creator>Sulkes, Aaron</creator><creator>Brenner, Baruch</creator><creator>Loven, David</creator><creator>Dreznik, Zeev</creator><creator>Nudelman, Israel</creator><creator>Shani, Adi</creator><creator>Fenig, Eyal</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20060601</creationdate><title>Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil</title><author>Yerushalmi, Rinat ; Idelevich, Efraim ; Dror, Ygael ; Stemmer, Salomon M. ; Figer, Arie ; Sulkes, Aaron ; Brenner, Baruch ; Loven, David ; Dreznik, Zeev ; Nudelman, Israel ; Shani, Adi ; Fenig, Eyal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4273-86ce037c37711459e40e76f44497493137e7148a036087dafc25275de16ae4e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Capecitabine</topic><topic>continuous-infusion 5-FU</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - adverse effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Diarrhea - chemically induced</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>preoperative chemoradiation</topic><topic>rectal cancer</topic><topic>Rectal Neoplasms - drug therapy</topic><topic>Rectal Neoplasms - pathology</topic><topic>Rectal Neoplasms - radiotherapy</topic><topic>Rectal Neoplasms - surgery</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yerushalmi, Rinat</creatorcontrib><creatorcontrib>Idelevich, Efraim</creatorcontrib><creatorcontrib>Dror, Ygael</creatorcontrib><creatorcontrib>Stemmer, Salomon M.</creatorcontrib><creatorcontrib>Figer, Arie</creatorcontrib><creatorcontrib>Sulkes, Aaron</creatorcontrib><creatorcontrib>Brenner, Baruch</creatorcontrib><creatorcontrib>Loven, David</creatorcontrib><creatorcontrib>Dreznik, Zeev</creatorcontrib><creatorcontrib>Nudelman, Israel</creatorcontrib><creatorcontrib>Shani, Adi</creatorcontrib><creatorcontrib>Fenig, Eyal</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yerushalmi, Rinat</au><au>Idelevich, Efraim</au><au>Dror, Ygael</au><au>Stemmer, Salomon M.</au><au>Figer, Arie</au><au>Sulkes, Aaron</au><au>Brenner, Baruch</au><au>Loven, David</au><au>Dreznik, Zeev</au><au>Nudelman, Israel</au><au>Shani, Adi</au><au>Fenig, Eyal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J. Surg. Oncol</addtitle><date>2006-06-01</date><risdate>2006</risdate><volume>93</volume><issue>7</issue><spage>529</spage><epage>533</epage><pages>529-533</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Background
We compared the efficacy and toxicity of oral capecitabine and continuous infusion of 5‐fluorouracil (5‐FU) in the preoperative chemoradiation treatment of patients with rectal cancer.
Patients and Methods
The files of 89 patients with rectal cancer, 43 treated preoperatively with oral capecitabine and 46 with intravenous 5‐FU, were reviewed, and the outcome of the groups was compared.
Results
There was no statistically significant difference in the complete pathological response rate between the capecitabine and the 5‐FU groups (30% vs. 17%, P = 0.15). The downstaging rate was higher in the capecitabine group (77% vs. 50%, P = 0.009). Toxicity was mild in both groups. The rate of Grade 3 gastrointestinal toxicity was similar in the two groups (diarrhea 2% vs. 4%, proctitis 5% vs. 7%), except for one patient in the 5‐FU group (2%) who developed a rectovaginal fistula. In the capecitabine group, one patient (2%) had Grade 3 hand‐foot syndrome, and another had an acute myocardial infarction. In the 5‐FU group, two patients (4%) had Grade 3 hematological toxicity, and three (6%) had complications from Port‐a‐Cath insertion.
Conclusion
Preoperative chemoradiation with oral capecitabine appears to be safe and well tolerated, and at least as good as continuous 5‐FU. J. Surg. Oncol. 2006;93:529–533. © 2006 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>16705722</pmid><doi>10.1002/jso.20503</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2006-06, Vol.93 (7), p.529-533 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_crossref_primary_10_1002_jso_20503 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Oral Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Capecitabine continuous-infusion 5-FU Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Diarrhea - chemically induced Drug Administration Schedule Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Humans Infusions, Intravenous Male Middle Aged Neoadjuvant Therapy preoperative chemoradiation rectal cancer Rectal Neoplasms - drug therapy Rectal Neoplasms - pathology Rectal Neoplasms - radiotherapy Rectal Neoplasms - surgery Retrospective Studies Treatment Outcome |
| title | Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T07%3A19%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preoperative%20chemoradiation%20in%20rectal%20cancer:%20Retrospective%20comparison%20between%20capecitabine%20and%20continuous%20infusion%20of%205-fluorouracil&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Yerushalmi,%20Rinat&rft.date=2006-06-01&rft.volume=93&rft.issue=7&rft.spage=529&rft.epage=533&rft.pages=529-533&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.20503&rft_dat=%3Cistex_cross%3Eark_67375_WNG_3ZXKX735_Q%3C/istex_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16705722&rfr_iscdi=true |